Puma Biotechnology, Inc.
PBYINASDAQHealthcare● Active
$6.85
$-0.18(-2.56%)
Market Cap$348661274
P/E Ratio—
52W High$7.9
52W Low$3.03
Puma Biotechnology, Inc. (PBYI) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PBYI · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.03B | $0.03B | $0.02B | $0.00B | ($0.03B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.01B | $0.03B |
| Change in Working Capital | ($0.01B) | ($0.00B) | ($0.02B) | ($0.04B) | ($0.00B) |
| Net Cash from Operations | $0.04B | $0.04B | $0.03B | ($0.02B) | $0.02B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) | $0.00B |
| Purchases of Investments | ($0.11B) | ($0.08B) | ($0.02B) | ($0.00B) | ($0.04B) |
| Sales of Investments | $0.07B | $0.06B | $0.02B | $0.02B | $0.03B |
| Net Cash from Investing | ($0.04B) | ($0.02B) | ($0.02B) | $0.01B | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.04B) | ($0.03B) | $0.00B | $0.00B | ($0.00B) |
| Net Cash from Financing | ($0.05B) | ($0.03B) | $0.00B | $0.01B | ($0.03B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.04B | $0.04B | $0.01B | ($0.02B) | $0.02B |
| FCF Margin %(computed) | 18.27% | 16.86% | 6.10% | -10.01% | 8.16% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Puma Biotechnology, Inc. data
About Puma Biotechnology, Inc. (PBYI) Cash Flow Statement
Puma Biotechnology, Inc. generated operating cash flow of $0.04B and free cash flow of $0.04B for 2025 — a FCF margin of 18.27%. Capital expenditure was ($0.00B).
Frequently asked questions
PBYI · 4 questionsPuma Biotechnology, Inc. generated free cash flow of $0.04B for 2025, up 7.4% year-over-year.
PBYI free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10